Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13589979 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL1058665 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL14433714 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL14493662 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL29838840 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL5811871 | 0.81 | POLB (0.69) | POLBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6865696 | 0.81 | POLB (0.68) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL1788313 | 0.79 | POLB (0.66) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL23406968 | 0.78 | POLB (0.64) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL503339 | 0.78 | POLB (0.64) | POLBALDH1A1TSHRLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714212-B2 | Chemical compounds derived from normemantine and use of same in the medical field | M2I DEVELOPMENT (FR) | 2017-07-25 | — | — | US | disclosed |
| US-9714212-B2 | Chemical compounds derived from normemantine and use of same in the medical field | M2I DEVELOPMENT (FR) | 2017-07-25 | — | — | US | disclosed |
| EP-2599774-B1 | CONDENSED PYRIDINE COMPOUNDS AS CB2 CANNABINOID RECEPTOR LIGANDS | ASTELLAS PHARMA INC (JP) | 2016-07-06 | — | — | EP | disclosed |
| US-20160107982-A1 | NOVEL CHEMICAL COMPOUNDS DERIVED FROM NORMEMANTINE AND USE OF SAME IN THE MEDICAL FIELD | M2I DEVELOPMENT (FR) | 2016-04-21 | — | — | US | disclosed |
| US-20160107982-A1 | NOVEL CHEMICAL COMPOUNDS DERIVED FROM NORMEMANTINE AND USE OF SAME IN THE MEDICAL FIELD | M2I DEVELOPMENT (FR) | 2016-04-21 | — | — | US | disclosed |
| US-8791106-B2 | Fused ring pyridine compound | ASTELLAS PHARMA INC. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20130143874-A1 | FUSED RING PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-06 | — | — | US | disclosed |
| EP-2599774-A1 | CONDENSED RING PYRIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2006097774-A1 | SYNTHETIC PEPTIDES CONTAINING UNNATURAL ADAMANTANE-RELATED AMINO ACIDS FOR USE AS ANTITUMOUR DRUGS | RUDJER BOSKOVIC INSTITUTE (HR) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143874-A1 | FUSED RING PYRIDINE COMPOUND | CNR2, CNR1, TRPV1 | POLB 4540/4885GRIN2D 1105/4885GRIN3B 1132/4885 |
| US-20160107982-A1 | NOVEL CHEMICAL COMPOUNDS DERIVED FROM NORMEMANTINE AND USE OF SAME IN THE MEDICAL FIELD | GRIN1, GRM1, GRIN3A | POLB 4464/4885GRIN2D 26/4885GRIN3B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.